title: Expression of XB130 in human ductal breast cancer.
abstract: OBJECTIVE
  XB130 is involved in gene regulation, cell proliferation, cell survival, cell migration, and tumorigenesis. In the present study, we first evaluated the expression of the XB130 and its prognostic significance in breast cancer. Then we evaluated whether XB130 could be a target for therapy in breast cancer.
  
  
  METHODS
  Immunohistochemistry was used to assess the level of XB130 protein in surgically resected, formalin-fixed, paraffin-embedded breast cancer specimens. Associations between XB130 and the postoperative prognosis of patients with breast cancer were evaluated. We evaluated the effect of XB130 inhibited by RNA interference on proliferation, invasion and apoptosis in vitro in a metastatic subclone of MCF-7 breast cancer cell line (LM-MCF-7). The effect of XB130 silencing alone or in combination with gemcitabine on LM-MCF-7 cells apoptosis was also investigated.
  
  
  RESULTS
  XB130 protein was present in the cytoplasm of malignant cells, and not in the normal breast tissues. There was correlation between the presence of XB130 in tumour cells and lymph node status, tumor classification and clinical stage. XB130 expression level was significantly associated with recurrence-free and overall survival. Furthermore, multivariate Cox regression analyses revealed that positive XB130 was an independent risk factor for overall survival and recurrence free survival. XB130 silencing alone inhibits tumor growth and induces apoptosis in the LM-MCF-7 cells. Depletion of the XB130 in combination with gemcitabine resulted in marked apoptotic and necrotic cell death in LM-MCF-7 cells.
  
  
  CONCLUSIONS
  XB130 could be useful as a prognostic marker of recurrence-free and overall survival in invasive breast cancer, as well as for the response to chemotherapy.
authors.affiliation: Department of Clinical Laboratory, The Affiliated Hospital of Weifang Medical College Weifang, China.
authors.forename: Jiacun
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Clinical Laboratory, The Affiliated Hospital of Weifang Medical College Weifang, China.
authors.forename: Wanli
authors.initials: W
authors.lastname: Sun
authors.affiliation: Department of Hepatobiliary Surgery, The People's Hospital of Zhangqiu Jinnan, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wei
authors.affiliation: Department of Ultrasonography, The People's Hospital of Zhangqiu Jinnan, China.
authors.forename: Xiurong
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Clinical Laboratory, The Affiliated Hospital of Weifang Medical College Weifang, China.
authors.forename: Hongjun
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Clinical Laboratory, The Affiliated Hospital of Weifang Medical College Weifang, China.
authors.forename: Zhengjun
authors.initials: Z
authors.lastname: Yi
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D002465:Cell Movement; D049109:Cell Proliferation; D016009:Chi-Square Distribution; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D061986:MCF-7 Cells; D008408:Mastectomy; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D034622:RNA Interference; D012307:Risk Factors; D015398:Signal Transduction; D013997:Time Factors; D014162:Transfection; D016896:Treatment Outcome; D015854:Up-Regulation; D000093542:Gemcitabine
chemical_list: C521126:AFAP1L2 protein, human; D048868:Adaptor Proteins, Signal Transducing; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Breast cancer; XB130; apoptosis; gemcitabine; invasion